-$1.02 EPS Expected for Assembly Biosciences Inc (ASMB) This Quarter
Analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to announce earnings of ($1.02) per share for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Assembly Biosciences’ earnings, with estimates ranging from ($1.15) to ($0.94). Assembly Biosciences reported earnings per share of ($0.71) in the same quarter last year, which suggests a negative year-over-year growth rate of 43.7%. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 7th.
On average, analysts expect that Assembly Biosciences will report full year earnings of ($4.12) per share for the current fiscal year, with EPS estimates ranging from ($4.51) to ($3.76). For the next financial year, analysts expect that the firm will report earnings of ($3.99) per share, with EPS estimates ranging from ($5.35) to ($2.27). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($1.30) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.42). Assembly Biosciences had a negative net margin of 457.20% and a negative return on equity of 66.34%. The company had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $3.30 million.
NASDAQ:ASMB traded down $0.33 during midday trading on Friday, hitting $36.13. 1,522 shares of the company traded hands, compared to its average volume of 183,742. Assembly Biosciences has a 12-month low of $27.00 and a 12-month high of $67.36. The firm has a market capitalization of $950.68 million, a PE ratio of -14.83 and a beta of 0.82.
In other news, VP Uri A. Lopatin sold 15,204 shares of the firm’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $40.09, for a total transaction of $609,528.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $38.50, for a total value of $38,500.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,744 shares of company stock worth $1,271,027. Insiders own 18.20% of the company’s stock.
Several institutional investors have recently made changes to their positions in ASMB. Bank of Montreal Can purchased a new position in shares of Assembly Biosciences during the second quarter valued at $145,000. Quantbot Technologies LP purchased a new position in shares of Assembly Biosciences during the first quarter valued at $154,000. Jane Street Group LLC purchased a new position in shares of Assembly Biosciences during the first quarter valued at $204,000. MetLife Investment Advisors LLC purchased a new position in shares of Assembly Biosciences during the second quarter valued at $282,000. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of Assembly Biosciences during the second quarter valued at $348,000. Hedge funds and other institutional investors own 65.21% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Featured Article: Return on Investment (ROI) Defined, Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.